

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1. (Currently amended) A targeting moiety comprising a conjugate of an antibody linked to a ligand-binding region of a receptor subunit selected from the group consisting of interleukin-2 receptor α (IL-2R α), interleukin-4 receptor α (IL-4R α), and interleukin-15 receptor α (IL-15R α), which antibody is specific for a cell marker specific to a targeted cell.
2. (Original) A targeting moiety as claimed in claim 1, comprising a covalent conjugate in which the antibody is covalently linked to the ligand-binding region of the receptor.
3. (Original) A targeting moiety as claimed in claim 1, comprising a fusion protein of the antibody and the ligand-binding region.
4. (Original) A targeting moiety as claimed in claim 1, comprising a bispecific antibody that has a first specificity for a cell marker specific to a targeted cell and a second specificity for the ligand-binding region.
5. (Original) A targeting moiety as claimed in claim 1, wherein the antibody is specific to CEA.
6. (Original) A targeting moiety as claimed in claim 1, wherein the antibody is specific to HLA-DR.
7. (Currently amended) A targeting moiety as claimed in claim 1, wherein the receptor subunit is IL-4R α .
8. (Original) A targeting moiety as claimed in claim 1, wherein the receptor subunit is IL-15R α .
9. (Original) A targeting moiety as claimed in claim 1, wherein the antibody is specific to HLA-DR and is linked to the ligand-binding region of IL-15R α .
10. (Original) A targeting moiety as claimed in claim 1, wherein the antibody is specific to CEA and is linked to the ligand-binding region of IL-15R α .
11. (Original) A targeting moiety as claimed in claim 1, wherein the antibody is specific to HLA-DR and is linked to the ligand-binding region of IL-4R α .

12. (Original) A targeting moiety as claimed in claim 1, wherein the antibody is specific to CEA and is linked to the ligand-binding region of IL-4R α .
13. (Original) A targeting moiety as claimed in claim 1, wherein the antibody is specific for a cell marker specific to a B-cell.
14. (Original) A targeting moiety as claimed in claim 1, wherein the antibody is specific for a cell marker specific to a malignant B-cell.
15. (Original) A targeting moiety as claimed in claim 1, wherein the antibody is specific for a cell marker specific to an activated B-cell.
16. (Original) A targeting moiety as claimed in claim 1, wherein the antibody is specific for a cell marker specific to a normal B-cell.
17. (Original) A targeting moiety as claimed in claim 1, wherein the antibody is specific for a cell marker specific to a T-cell.
18. (Original) A targeting moiety as claimed in claim 1, wherein the antibody is specific for a cell marker specific to a malignant T-cell.
19. (Original) A targeting moiety as claimed in claim 1, wherein the antibody is specific for a cell marker specific to an activated T-cell.
20. (Original) A composition comprising a targeting moiety according to claim 1, and a pharmaceutically acceptable carrier.
21. (Original) A composition comprising a targeting moiety according to claim 7, and a pharmaceutically acceptable carrier.
22. (Original) A composition comprising a targeting moiety according to claim 8, and a pharmaceutically acceptable carrier.
23. (Original) A kit comprising a conjugate of IL-15 linked to a drug, radionuclide or toxin, and a targeting moiety comprising an antibody specific for a cell marker specific to a targeted cell, linked to the ligand-binding region of IL-15R α .
24. (Original) A kit as claimed in claim 23, wherein the antibody is specific for a cell marker specific to a B-cell.
25. (Original) A kit as claimed in claim 23, wherein the antibody is specific for a cell marker specific to a malignant B-cell.

26. (Original) A kit as claimed in claim 23, wherein the antibody is specific for a cell marker specific to an activated B-cell.

27. (Original) A kit as claimed in claim 23, wherein the antibody is specific for a cell marker specific to a normal B-cell.

28. (Original) A kit as claimed in claim 23, wherein the antibody is specific for a cell marker specific to a T-cell.

29. (Original) A kit as claimed in claim 23, wherein the antibody is specific for a cell marker specific to a malignant T-cell.

30. (Original) A method of treatment for cancer or an immunologically-mediated or infectious disease, comprising:

first administering to a subject in need of such treatment a targeting moiety comprising a antibody specific for a cell marker specific to a targeted cell, linked to the ligand-binding region of IL-15R α , and then administering to the subject a therapeutically effective amount of a conjugate of IL-15 linked to a drug, radionuclide or toxin.

31. (Original) A method as claimed in claim 30, wherein the antibody is specific for a cell marker specific to a B-cell.

32. (Original) A method as claimed in claim 30, wherein the antibody is specific for a cell marker specific to a malignant B-cell.

33. (Original) A method as claimed in claim 30, wherein the antibody is specific for a cell marker specific to an activated B-cell.

34. (Original) A method as claimed in claim 30, wherein the antibody is specific for a cell marker specific to a normal B-cell.

35. (Original) A method as claimed in claim 30, wherein the antibody is specific for a cell marker specific to a T-cell.

36. (Original) A method as claimed in claim 30, wherein the antibody is specific for a cell marker specific to a malignant T-cell.

37. (Original) A targeting moiety comprising a conjugate of an antibody linked to a ligand-binding region of interleukin-13 receptor α (IL-13R α), which antibody is specific to HLA-DR.

38. (Original) A composition comprising a targeting moiety according to claim 18, and a pharmaceutically acceptable carrier.